Drugs for Dengue Hemorrhagic Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 24)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Histamine |
Approved, Investigational |
Phase 4 |
|
51-45-6, 75614-87-8 |
774 |
Synonyms:
.beta.-Imidazolyl-4-ethylamine
[3H]histamine
1avn
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1qft
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-imidazolyl)ethylamine
2-(4-Imidazolyl)ethylamine
2-[4-Imidazolyl]ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-imidazoleethylamine
4-Imidazoleethylamine
51-45-6
53290_FLUKA
5-imidazoleethylamine
5-Imidazoleethylamine
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
beta-aminoethylglyoxaline
beta-Aminoethylglyoxaline
beta-aminoethylimidazole
beta-Aminoethylimidazole
beta-aminothethylglyoxaline
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
bmse000744
BSPBio_001117
BSPBio_002124
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
histamine
|
Histamine
Histamine (DCF)
Histamine [USAN]
Histamine Base
Histamine, Free Base
Histaminum
Histaminum (TN)
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L000292
L-histamine
Lopac0_000595
Lopac-H-7250
LS-75835
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
nchembio.87-comp54
nchembio714-comp1
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
Spectrum_000845
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
ST073926
STK346752
STOCK5S-55669
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
β-Imidazolyl-4-ethylamine
|
|
2 |
|
Ketotifen |
Approved |
Phase 4 |
|
34580-13-7, 34580-14-8 |
3827 |
Synonyms:
10-(1-Methyl-4-piperidinylidene)-5H-benzo[1,2]cyclohepta[3,4-b]thiophen-4-one
10H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-, (2E)-2-butenedioate (1:1)
116655-74-4
34580-13-7
4-(1-Methyl-4-piperidylidene)-9-hydrobenzo[a]thiopheno[3,2-d][7]annulen-10-one
4-(1-methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one
4-(1-Methyl-piperidin-4-ylidene)-4,9-dihydro-1-thia-benzo[f]azulen-10-one
4,9-Dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one
4,9-Dihydro-4-(1-methyl-4-piperidylidene)-10H-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one
AB00053575
AC-15945
AC1L1GSZ
AKOS000541268
Alaway
Alaway (TN)
BAS 00444483
BIDD:GT0509
BPBio1_000575
BRD-K28936863-051-05-8
BRN 3983897
BSPBio_000521
BSPBio_002964
C19H19NOS
CAS-34580-14-8
CHEBI:112957
CHEMBL534
CID3827
D08105
DB00920
DivK1c_000111
EINECS 252-099-7
Fumarate, ketotifen
HC 20-511
HMS2090F16
HSDB 7283
IDI1_000111
KBio1_000111
KBio2_000906
KBio2_003474
KBio2_006042
KBio3_002184
KBioGR_001289
KBioSS_000906
ketotifen
Ketotifen
|
Ketotifen (INN)
Ketotifen [INN:BAN]
Ketotifen fumarate
Ketotifene
Ketotifene [INN-French]
Ketotifene fumarate
Ketotifeno
Ketotifeno [INN-Spanish]
Ketotifenum
Ketotifenum [INN-Latin]
Ketotifin
Ketotiphen
Ketotiphene
L000753
Lopac0_000706
Lopac-K-2628
LS-33820
MolPort-001-933-278
NCGC00015580-01
NCGC00015580-02
NCGC00015580-03
NCGC00015580-09
NCGC00022572-02
NCGC00022572-04
NCGC00022572-05
NINDS_000111
Oprea1_335550
Oprea1_553550
Prestwick0_000371
Prestwick1_000371
Prestwick2_000371
Prestwick3_000371
SPBio_001275
SPBio_002442
Spectrum_000426
Spectrum2_001198
Spectrum3_001382
Spectrum4_000805
Spectrum5_001395
STK048448
STOCK1S-14132
Tocris-0784
UNII-X49220T18G
Zaditen
Zaditor
|
|
3 |
|
Histamine Antagonists |
|
Phase 4 |
|
|
|
4 |
|
Histamine Phosphate |
|
Phase 4 |
|
51-74-1 |
65513 |
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
|
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
LS-78569
UNII-QWB37T4WZZ
|
|
5 |
|
Anti-Allergic Agents |
|
Phase 4 |
|
|
|
6 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
7 |
|
Histamine H1 Antagonists |
|
Phase 4 |
|
|
|
8 |
|
Dermatologic Agents |
|
Phase 4 |
|
|
|
9 |
|
tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
|
Synonyms:
ácido tánico
Gallotannic acid
|
|
|
10 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl PABA
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
11 |
|
Montelukast |
Approved |
Phase 2, Phase 3 |
|
158966-92-8 |
5281040 |
Synonyms:
(R-(e))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetate
(R-(e))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
(R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
{1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid
1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
1-[[[(1 R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetate
1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid
1-[[[(1 R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid
1-[[[(1 R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulphanyl]methyl]cyclopropaneacetate
1-[[[(1 R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulphanyl]methyl]cyclopropaneacetic acid
151767-02-1 (sodium)
158966-92-8
2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
AC1NQXXW
Apxi toxin
BIDD:GT0394
Brondilat
Brondilat (TN)
C07482
C35H36ClNO3S
Cahill may roberts brand OF montelukast sodium
CHEBI:50730
CHEMBL787
CID5281040
|
D08229
DB00471
HMS2089D07
HSDB 7582
LS-173539
Merck brand OF montelukast sodium
Merck frosst brand OF montelukast sodium
Merck sharp and dohme brand OF montelukast sodium
MK 0476
MK-0476
Montair
montelukast
Montelukast
Montélukast
Montelukast (INN)
Montelukast [INN:BAN]
Montelukast sodium
Montelukastum
Singulair
Singular
sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate
Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate
UNII-MHM278SD3E
|
|
12 |
|
Heptavalent Pneumococcal Conjugate Vaccine |
|
Phase 3 |
|
|
|
13 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
14 |
|
Respiratory System Agents |
|
Phase 2, Phase 3 |
|
|
|
15 |
|
Anti-Asthmatic Agents |
|
Phase 2, Phase 3 |
|
|
|
16 |
|
Hormone Antagonists |
|
Phase 2, Phase 3 |
|
|
|
17 |
|
Hormones |
|
Phase 2, Phase 3 |
|
|
|
18 |
|
Leukotriene Antagonists |
|
Phase 2, Phase 3 |
|
|
|
19 |
|
Vaccines |
|
Phase 3 |
|
|
|
20 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
21 |
|
Ivermectin |
Approved, Investigational, Vet_approved |
Phase 2 |
|
70288-86-7 |
6474909 |
Synonyms:
(2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-20,20b-dihydroxy-5',6,8,19-tetramethyl-6'-[(1S)-1-methylpropyl]-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside
71827-03-7
AB00513813
AC1MJ4GR
AC1N7O27
BPBio1_000322
BRD-K24652731-001-02-7
BSPBio_000292
CHEMBL341047
CID11957587
CID4330618
CID6321424
CID6419971
CID6427057
EU-0100693
FT-0082656
HMS1568O14
HMS2089M09
I 8898
I8898_SIGMA
|
Ivermectin
IVERMECTIN
Ivermectina
Ivermectine
Ivermectinum
Lopac0_000693
MK-933
MLS001333247
MLS001333248
MLS002153248
MolPort-006-394-715
NCGC00094047-01
NCGC00094047-02
NCGC00094047-03
Prestwick_516
Prestwick2_000156
Prestwick3_000156
S1351_Selleck
SMR000857211
|
|
22 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
23 |
|
Antiparasitic Agents |
|
Phase 2 |
|
|
|
24 |
|
Hemostatics |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show all 44)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN) |
Unknown status |
NCT02673840 |
Phase 4 |
Ketotifen;Placebo |
2 |
The Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as a Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients |
Unknown status |
NCT00966628 |
Phase 3 |
Hypertonic sodium lactate;Ringer's lactate |
3 |
Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia |
Completed |
NCT01373281 |
Phase 3 |
|
4 |
Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia |
Completed |
NCT01254422 |
Phase 3 |
|
5 |
Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru |
Completed |
NCT01436396 |
Phase 3 |
|
6 |
Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaximâ„¢) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico |
Completed |
NCT01411241 |
Phase 3 |
|
7 |
Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America |
Completed |
NCT01374516 |
Phase 3 |
|
8 |
Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia |
Completed |
NCT01134263 |
Phase 3 |
|
9 |
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia |
Completed |
NCT02993757 |
Phase 3 |
|
10 |
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico |
Completed |
NCT02979535 |
Phase 3 |
|
11 |
Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients: a Multicenter Randomized, Double-blind, Placebo Controlled, Superiority Trial |
Recruiting |
NCT04673422 |
Phase 2, Phase 3 |
Montelukast;Placebo |
12 |
Albumin 5% as Resuscitation in Adult Dengue Fever Patients With Plasma Leakage |
Recruiting |
NCT04076254 |
Phase 3 |
Albumins;Fluid |
13 |
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines |
Terminated |
NCT02992418 |
Phase 3 |
|
14 |
Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients |
Unknown status |
NCT03432442 |
Phase 2 |
Ivermectin |
15 |
A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Comparison of Recombinant Factor VIIa (NovoSeven®) and Standard Haemostatic Replacement Therapy in Patients With Dengue Haemorrhagic Fever |
Completed |
NCT01601613 |
Phase 2 |
activated recombinant human factor VII;placebo |
16 |
Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in South America |
Completed |
NCT01187433 |
Phase 2 |
|
17 |
Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years |
Completed |
NCT00740155 |
Phase 2 |
|
18 |
Safety of ChimeriVaxâ„¢ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine |
Completed |
NCT00730288 |
Phase 2 |
|
19 |
Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US |
Completed |
NCT00617344 |
Phase 2 |
|
20 |
Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children |
Completed |
NCT00468858 |
Phase 2 |
|
21 |
Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines |
Completed |
NCT01064141 |
Phase 2 |
|
22 |
Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine |
Completed |
NCT01943825 |
Phase 2 |
|
23 |
Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1 , 2 , or 3 Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines |
Completed |
NCT02628444 |
Phase 2 |
|
24 |
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America |
Completed |
NCT02623725 |
Phase 2 |
|
25 |
Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India. |
Completed |
NCT01550289 |
Phase 2 |
|
26 |
Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults. |
Completed |
NCT01488890 |
Phase 2 |
|
27 |
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore |
Completed |
NCT02824198 |
Phase 2 |
|
28 |
Immunogenicity and Safety of ChimeriVaxâ„¢ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru |
Completed |
NCT00788151 |
Phase 2 |
|
29 |
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America |
Completed |
NCT00993447 |
Phase 2 |
|
30 |
Immunogenicity and Safety of ChimeriVaxâ„¢ Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam |
Completed |
NCT00875524 |
Phase 2 |
|
31 |
Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand |
Completed |
NCT00842530 |
Phase 2 |
|
32 |
Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore |
Completed |
NCT00880893 |
Phase 2 |
|
33 |
Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Aged 18 to 50 Years in Brazil |
Active, not recruiting |
NCT02741128 |
Phase 2 |
|
34 |
Evaluation of the Safety and Immunogenicity of Heterologous Dengue Vaccine Administration in Dengue Immune Individuals |
Completed |
NCT00458120 |
Phase 1 |
|
35 |
Phase I Evaluation of the Safety and Immunogenicity of rDEN4delta30 Lot# 109A, a Live Attenuated DEN4 Vaccine, in Healthy Flavivirus-naïve Adult Volunteers. |
Completed |
NCT00919178 |
Phase 1 |
|
36 |
Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore |
Completed |
NCT04048837 |
|
|
37 |
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children in India |
Completed |
NCT01477671 |
|
|
38 |
Long-Term Follow-Up of Hospitalized Dengue and Safety in Thai Children Who Were Included in an Efficacy Study of a Tetravalent Dengue Vaccine |
Completed |
NCT01983553 |
|
|
39 |
Laboratory Diagnosis and Prognosis of Severe Dengue |
Completed |
NCT01421732 |
|
|
40 |
Association of Host Genetics With Vaccine Efficacy, and Evaluation of Immune Correlates of Risk From the First Proof of Concept Efficacy Study With a Tetravalent Dengue Vaccine |
Completed |
NCT02827162 |
|
|
41 |
Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose. |
Recruiting |
NCT01099852 |
|
|
42 |
Effectiveness of the Tetravalent Dengue Vaccine, CYD-TDV (Dengvaxia®) in the Philippines |
Recruiting |
NCT03803618 |
|
|
43 |
Effect of Baseline Dengue Serostatus Among Tetravalent Dengue Vaccine CYDTDV (Dengvaxia®) Recipients on Subsequent Virologically Confirmed Dengue in the Philippines |
Active, not recruiting |
NCT03465254 |
|
|
44 |
Post-Authorization Safety Study: Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine |
Active, not recruiting |
NCT02948933 |
|
|
Cochrane evidence based reviews: severe dengue
|